Pharmaceutical Technology

NOVEMBER 29, 2022

The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts. Nearly 9,000 men with prostate cancer will be eligible to receive this treatment.

Chemotherapy 118

Chemotherapy Hospitals 118

Express Pharma

JULY 17, 2023

Clinexel Life Sciences, a leading clinical research organisation, is supporting and managing the clinical development programme for global approvals. Sathgen aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.

Chemotherapy 84

Chemotherapy 84

pharmaphorum

NOVEMBER 29, 2021

A web-based digital tool called Helix could help clinicians identify patients with prostate cancer who would benefit from genetic testing and counselling, according to researchers in the US. In addition, just 43% correctly identified that BRCA2 mutations – treated with PARP inhibitors – are associated with aggressive prostate cancers.

98

98

Pharmacy Times

NOVEMBER 7, 2023

With precision medicine, patients undergoing treatment are living longer without disease recurrence or progression and with fewer adverse effects, resulting in preservation of quality of life.

49

49

European Pharmaceutical Review

JANUARY 9, 2024

Pfizer’s oral poly ADP-ribose polymerase (PARP) inhibitor TALZENNA ® (talazoparib), in combination with XTANDI ® (enzalutamide) has been approved for prostate cancer by the European Commission (EC). This results in less cancer cell growth and death, according to Pfizer in a statement.

Chemotherapy 87

Chemotherapy 87

European Pharmaceutical Review

MARCH 21, 2023

AstraZeneca and MSD’s treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in first-line mCRPC.

Chemotherapy 93

Chemotherapy Hospitals 93

European Pharmaceutical Review

DECEMBER 5, 2022

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death.

Chemotherapy 99

Chemotherapy Compounding Labelling Drug Development 99

Pharmacy Times

SEPTEMBER 28, 2022

There were approximately 250,000 new cases of prostate cancer identified in the United States in 2021, which is considered approximately 13% of all cancer cases.

47

47

Express Pharma

AUGUST 25, 2023

When breast cancer cells spread to other parts of the body it is called secondary or metastatic breast cancer and although treatable cannot be cured Researchers at the University of Sheffield are testing new combinations of drugs to treat breast cancer that’s spread to the bone with the help of funding from Breast Cancer Now.

89

89

pharmaphorum

NOVEMBER 27, 2022

There are over 52,000 cases of prostate cancer each year in the UK alone, with over 15,000 new cases of metastatic prostate cancer confirmed annually. There are over 52,000 cases of prostate cancer each year in the UK alone, with over 15,000 new cases of metastatic prostate cancer confirmed annually.

Hospitals 98

Hospitals 98

Pharmaceutical Technology

APRIL 17, 2024

Everolimus is under clinical development by Novartis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

52

52

Pharmaceutical Technology

FEBRUARY 7, 2024

Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.

52

52

European Pharmaceutical Review

AUGUST 17, 2022

The MHRA has also issued a licence in Great Britain for Locametz ® (gozetotide) which, after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of PSMA-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer. percent), dry mouth (38.8

Chemotherapy 115

Chemotherapy Compounding Labelling 115

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer.

Drug Development 98

Drug Development 98

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. The post NICE says no to Lynparza in prostate cancer, creating UK access divide appeared first on.

Chemotherapy 111

Chemotherapy 111

LifeProNow

MARCH 27, 2023

With Nubeqa (darolutamide) as a key growth driver it is gearing up to become a leader in prostate cancer, the second most commonly diagnosed cancer in men. Nubeqa has the potential to become the standard of care for prostate cancer patients from the early- to the late-stage of this disease. EU, Japan, and China.

Bioethics 130

Bioethics Compounding Diabetes 130

pharmaphorum

SEPTEMBER 22, 2021

Software that can help pathologists detect prostate cancer from slides of biopsies more effectively has been approved by the FDA. The software – called Paige Prostate – is the first artificial intelligence-based to be approved by the FDA for this purpose, according to the US regulator.

108

108

Pharmaceutical Technology

JUNE 1, 2023

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD ’s Lynparza (olaparib), with standard therapies for treating BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is the second-most common cancer reported in men.

Chemotherapy 97

Chemotherapy 97

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Research Laboratories 105

Research Laboratories Vaccines 105

European Pharmaceutical Review

DECEMBER 21, 2022

Positive Phase III trial results for metastatic castration-resistant prostate cancer. The safety and tolerability of Lynparza in combination with abiraterone in PROpel was in line with that observed in prior clinical trials and the known profiles of the individual medicines.

Chemotherapy 96

Chemotherapy Hospitals 96

Express Pharma

MARCH 19, 2024

billion to shore up its rare disease portfolio AstraZeneca said on Tuesday it will buy clinical stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. billion to shore up its rare disease portfolio.

Chemotherapy 102

Chemotherapy 102

Pharma Times

MAY 10, 2021

Researchers are initiating clinical trials to evaluate whether targeting the CD38 pathway can provide benefit for people with prostate cancer

112

112

Pharma Leaders

APRIL 25, 2023

The FDA has granted Fast Track designation to Lantheus and Point Biopharma’s 177Lu-PNT2002 for the treatment of metastatic castration-resistant prostate cancer. 117Lu-PNT2002 is currently under a phase 3 clinical trial setting, with enrollment complete and top-line data expected in the second half of this year.

52

52

Pharmaceutical Technology

FEBRUARY 19, 2024

AC-0176 is under clinical development by Accutar Biotechnology and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

FEBRUARY 7, 2024

CONV 01-alpha is under clinical development by Convergent Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

AUGUST 8, 2022

The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients. in trial subjects versus those who received ADT plus docetaxel.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The post Bayer triples sales forecast for prostate cancer drug Nubeqa appeared first on.

Chemotherapy 98

Chemotherapy Labelling Diabetes 98

Pharmafile

OCTOBER 4, 2023

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of clinical and preclinical-stage radioligand therapies for the treatment of cancer.

69

69

pharmaphorum

AUGUST 9, 2022

Magnetic resonance imaging (MRI) technology specialist Bot Image has won FDA approval for its artificial intelligence-powered software ProstatID, used for the detection and diagnosis of prostate cancer. The post FDA okays ProstatID software for detecting prostate cancer in MRI appeared first on.

83

83

pharmaphorum

SEPTEMBER 28, 2020

Shares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of efficacy in advanced prostate cancer in its first clinical trial. The trial involved patients with locally advanced or metastatic prostate cancer, so received VAL201 in rising doses by subcutaneous injection.

Hospitals 124

Hospitals 124

pharmaphorum

JANUARY 26, 2023

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co’s checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. It remains ongoing with updated results due in the coming months.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

Pharmaceutical Technology

FEBRUARY 27, 2023

Finnish pharmaceutical firm Orion has received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide plus androgen deprivation therapy (ADT) along with docetaxel to treat metastatic prostate cancer. It also demonstrated consistent benefits across clinically relevant secondary endpoints of the trial.

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

AUGUST 14, 2023

The US Food and Drug Administration (FDA) has approved Janssen’s Akeega (niraparib and abiraterone acetate), for the treatment of adult patients BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). acquired by GlaxoSmithKline in 2019) for exclusive rights to niraparib in prostate cancer treatment.

52

52

Pharmaceutical Technology

FEBRUARY 7, 2024

Cyclosam is under clinical development by QSAM Therapeutics and currently in Phase I for Metastatic Prostate Cancer.

40

40

Pharmaceutical Technology

APRIL 6, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending AstraZeneca’s olaparib to treat early breast cancer and metastatic prostate cancer. It also updates NICE’s recommendation for olaparib for prostate cancer patients with BRCA1 or BRCA2 mutations.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Business Review

DECEMBER 28, 2023

POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such therapies in the clinical and preclinical stages of development. Apart from these assets, POINT also has various other programmes in the early stages of clinical and preclinical development.

59

59

Pharmaceutical Technology

DECEMBER 25, 2023

ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40